CMC Biologics announces development and manufacturing agreement with Harpoon Therapeutics. CMC ICOS Biologics, Inc., a clinical and commercial manufacturer of therapeutic proteins, and Harpoon Therapeutics, an immuno-oncology company using its proprietary TriTAC technology platform to discover and develop novel biologics for the treatment of cancer, have entered into an agreement for the development and manufacturing of HPN424, HPN536,…